Potentially, tumor expression of CTLA-4 and PD-L1 can provide a rationale for screening of the tumor samples to identify candidates for the targeted therapies and further provide rationales for investigation of the anti-immune checkpoint treatments. This evidence concerns the gene CTLA4 and neoplasm.